Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

Summary

The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.

Timeline

Start

2024-01-22

Primary completion

2025-09-23

Completion

2025-09-23

Drugs

Indications